- Benuvia Operations has appointed Terry Novak as Chief Executive Officer, replacing Darwin Richardson.
- Novak brings 30 years of experience in the pharmaceutical and CDMO industries to his new role.
Benuvia Operations, LLC, a company specialising in the development and manufacturing of cannabinoid, psychedelic, and controlled substance products, has announced the appointment of Terry Novak as its new Chief Executive Officer.
Terry Novak, with 30 years of executive leadership experience, previously held senior positions at various pharmaceutical and CDMO companies. His roles include Chief Commercial & Operations Officer at Bright Path Laboratories, President at Norwich Pharmaceuticals, and President for North America at Patheon. Novak also has a background in sales management from his early career at Bristol-Myers Squibb. He is currently a board member of several life sciences companies and serves on the North Carolina Biotech Advisory Board.
“Terry is an accomplished industry executive with deep commercial, manufacturing, and transaction expertise and a significant track record building and scaling CDMO businesses,” said Todd Davis, lead director of Benuvia. “We are honoured to have someone of Terry’s calibre lead Benuvia forward.”
In 2024, Benuvia has made several strategic moves, including partnerships with Bright Green Corporation for DEA-approved extracts, Chromocell Therapeutics for novel pain treatments, Societal CDMO, Inc. for co-marketing services, and PharmaCielo Ltd. for producing cGMP pharmaceutical-grade APIs. Novak’s appointment is expected to drive further growth and expansion in Benuvia’s service offerings.
Overview of outsourcing trends 
